Cogent Biosciences, Inc. (COGT) is listed on NASDAQ in Pharmaceutical Stocks. It is $34.67, -6.52%, with a $6.0B market cap. RSI is 38.7, near oversold. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 38.7 Near Oversold
Market Cap $6.0B
Volume 1.4M
Fundamentals — 10-Q Q2 2026
Revenue --
Net Income $-193.8M
EPS $-1.05
Debt / Equity 0.4x
P/E Ratio -33.0x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director | Sell | 7,000,000 | $34.66 | $242.6M | 2026 Mar 31 |
| Green John L. | Chief Financial Officer | Sell | 77,000 | $38.68 | $3.0M | 2025 Dec 26 |
| Sachs Jessica | Chief Medical Officer | Sell | 82,642 | $38.70 | $3.2M | 2025 Dec 26 |
| Kearns Evan | Chief Legal Officer | Sell | 65,000 | $38.70 | $2.5M | 2025 Dec 26 |
| Robinson John Edward | Chief Scientific Officer | Sell | 90,000 | $38.74 | $3.5M | 2025 Dec 26 |
| Fairmount Funds Management LLC | Director | Buy | 2,777,777 | $9.00 | $25.0M | 2025 Jul 10 |
| Pinnow Cole | Chief Commercial Officer | Buy | 43,750 | $7.60 | $332,500 | 2025 Jan 14 |
| Fairmount Funds Management LLC | 10% Owner | Buy | 800,000 | $12.00 | $9.6M | 2023 Jun 9 |
| Fairmount Funds Management LLC | 10% Owner | Buy | 1,200,000 | $8.25 | $9.9M | 2022 Jun 16 |
| Green John L. | Chief Financial Officer | Sell | 17,813 | $8.86 | $157,823 | 2021 Apr 26 |
| Campana Dario | 10% Owner | Sell | 2,000,000 | $0.39 | $787,280 | 2020 May 12 |
| Schulke Ryan | Chief Executive Officer | Buy | 100,000 | $2.54 | $254,000 | 2018 Mar 29 |
| Conlin Matthew | President | Buy | 40,000 | $2.54 | $101,579 | 2018 Mar 29 |
| Schulke Ryan | Chief Executive Officer | Buy | 100,000 | $2.58 | $258,000 | 2018 Mar 28 |
| Dell Jeffrey Alan | Chief Information Officer | Buy | 2,000 | $3.10 | $6,200 | 2018 Feb 15 |
| Conlin Matthew | 10% Owner | Buy | 20,000 | $2.81 | $56,200 | 2018 Feb 13 |
| Brauser Michael | Director | Buy | 20,000 | $2.85 | $57,000 | 2018 Feb 13 |
| Schulke Ryan | Director | Buy | 100,000 | $2.93 | $293,000 | 2018 Feb 13 |
| Brauser Michael | Director | Buy | 18,000 | $3.65 | $65,610 | 2017 Dec 15 |
| Dubner Derek | Chief Executive Officer | Buy | 1,000 | $3.73 | $3,730 | 2017 Dec 14 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $91.15 | 37.5 | $6.0B |
| | $280.77 | 42.4 | $5.6B |
| | $144.22 | 47.1 | $9.3B |
| | $40.94 | 41.9 | $5.5B |
Take COGT further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put COGT in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Cogent Biosciences, Inc. next reports.
Set alerts on COGT
Get notified when Cogent Biosciences, Inc. hits your price targets or technical conditions are met.
Get Started Free